Several pathways known to be important to glioma development were also at the top of the significant canonical pathways list, including ‘WNT/beta-Catenin Signaling’ (CD44, CDH2, DVL3, LRP1, MYC, SOX4, SOX9, SOX13, TCF3, TCF4, TLE3, WNT5A) and ‘mTOR Signaling’ (EIF3B, EIF3E, EIF3F, EIF4A1, HIF1A, PRKD1, RHOC, RND2, RND3). This evidence concerns the gene CDH2 and glioma.